down arrow

Treace Medical Concepts, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US89455T1097
USD
2.57
0.08 (3.21%)

Dec 19

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

2.432.61

52 Week

2.4310.79
Valuation
Technical
Day's Volume

CASH

1.86 M

Shareholding (Mar 2025)

FII

8.10%

Held by 80 FIIs

DII

66.66%

Held by 30 DIIs

Promoter

0.58%

How big is Treace Medical Concepts, Inc.?

22-Jun-2025

As of Jun 18, Treace Medical Concepts, Inc. has a market capitalization of 342.20 million and reported net sales of 210.82 million with a net profit of -52.99 million over the latest four quarters.

Market Cap: As of Jun 18, Treace Medical Concepts, Inc. has a market capitalization of 342.20 million, categorized as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Treace Medical Concepts, Inc. reported net sales of 210.82 million and a net profit of -52.99 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 112.89 million and total assets of 217.09 million.

Read More

What does Treace Medical Concepts, Inc. do?

22-Jun-2025

Treace Medical Concepts, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $53 million and a net loss of $16 million as of March 2025. The company has a market cap of $342.20 million and does not pay dividends.

Overview:<BR>Treace Medical Concepts, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 53 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -16 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 342.20 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.20 <BR>Return on Equity: -50.25% <BR>Price to Book: 3.25<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Read More

Should I buy, sell or hold Treace Medical Concepts, Inc.?

22-Jun-2025

Is Treace Medical Concepts, Inc. technically bullish or bearish?

20-Sep-2025

As of September 2, 2025, Treace Medical Concepts, Inc. shows a mildly bearish trend with mixed indicators, underperforming the S&P 500 year-to-date at -3.36% but outperforming it over the past year with a return of 31.2%.

As of 2 September 2025, the technical trend for Treace Medical Concepts, Inc. has changed from sideways to mildly bearish. The weekly MACD and KST are mildly bullish, but the monthly MACD and Bollinger Bands indicate a bearish stance. The daily moving averages are mildly bearish, and the weekly OBV is also mildly bearish. Overall, the indicators present a mixed picture, with a bearish bias prevailing in the longer-term metrics.<BR><BR>In terms of performance, the stock has underperformed the S&P 500 year-to-date, with a return of -3.36% compared to the S&P's 12.22%. However, over the past year, Treace has outperformed the index with a return of 31.2% versus 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Flat results in Jun 25

  • DEBT-EQUITY RATIO (HY) Highest at 0.82 %
  • INVENTORY TURNOVER RATIO(HY) Lowest at 1.02 times
2

Risky - Negative EBITDA

3

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 449 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.13

stock-summary
Return on Equity

-50.33%

stock-summary
Price to Book

4.60

Revenue and Profits:
Net Sales:
47 Million
(Quarterly Results - Jun 2025)
Net Profit:
-17 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-62.7%
0%
-62.7%
6 Months
-52.93%
0%
-52.93%
1 Year
-62.75%
0%
-62.75%
2 Years
-76.55%
0%
-76.55%
3 Years
-88.77%
0%
-88.77%
4 Years
-84.46%
0%
-84.46%
5 Years
0%
0%
0.0%

Treace Medical Concepts, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Treace Medical Concepts Hits New 52-Week Low at $3.41

Treace Medical Concepts Hits New 52-Week Low at $3.41

Treace Medical Concepts, Inc. has reached a new 52-week low, reflecting ongoing challenges in the Pharmaceuticals & Biotechnology sector. The company has experienced a significant decline in performance over the past year, with negative financial metrics and high institutional holdings, indicating a complex financial landscape.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
36.79%
EBIT Growth (5y)
-268.92%
EBIT to Interest (avg)
-7.01
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.20
Sales to Capital Employed (avg)
1.09
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
92.31%
ROCE (avg)
1.06%
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.47
EV to EBIT
-6.59
EV to EBITDA
-7.96
EV to Capital Employed
4.07
EV to Sales
1.64
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-61.74%
ROE (Latest)
-50.25%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Bearish
Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 55 Schemes (24.66%)

Foreign Institutions

Held by 80 Foreign Institutions (8.1%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 6.52% vs 5.95% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 17.92% vs -72.36% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "47.40",
          "val2": "44.50",
          "chgp": "6.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-14.40",
          "val2": "-19.30",
          "chgp": "25.39%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.30",
          "val2": "1.30",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-17.40",
          "val2": "-21.20",
          "chgp": "17.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-358.20%",
          "val2": "-481.00%",
          "chgp": "12.28%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 11.92% vs 31.95% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -12.53% vs -15.65% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "209.40",
          "val2": "187.10",
          "chgp": "11.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-47.30",
          "val2": "-46.10",
          "chgp": "-2.60%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "5.30",
          "val2": "5.20",
          "chgp": "1.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.10",
          "val2": "-0.20",
          "chgp": "50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-55.70",
          "val2": "-49.50",
          "chgp": "-12.53%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-266.00%",
          "val2": "-274.80%",
          "chgp": "0.88%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
47.40
44.50
6.52%
Operating Profit (PBDIT) excl Other Income
-14.40
-19.30
25.39%
Interest
1.30
1.30
Exceptional Items
0.00
0.00
Consolidate Net Profit
-17.40
-21.20
17.92%
Operating Profit Margin (Excl OI)
-358.20%
-481.00%
12.28%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 6.52% vs 5.95% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 17.92% vs -72.36% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
209.40
187.10
11.92%
Operating Profit (PBDIT) excl Other Income
-47.30
-46.10
-2.60%
Interest
5.30
5.20
1.92%
Exceptional Items
-0.10
-0.20
50.00%
Consolidate Net Profit
-55.70
-49.50
-12.53%
Operating Profit Margin (Excl OI)
-266.00%
-274.80%
0.88%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 11.92% vs 31.95% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -12.53% vs -15.65% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Treace Medical Concepts, Inc. stock-summary
stock-summary
Treace Medical Concepts, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."